Trial Profile
A Phase II Study of Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Malignant melanoma
- Focus Therapeutic Use
- 17 Feb 2021 Planned End Date changed from 1 Sep 2020 to 1 Dec 2025.
- 17 Feb 2021 Planned primary completion date changed from 1 Sep 2020 to 1 Dec 2021.
- 19 Dec 2019 Planned End Date changed from 1 Dec 2019 to 1 Sep 2020.